Ana P Davel1, Imran J Anwar, Iris Z Jaffe. 1. aMolecular Cardiology Research Institute, Tufts Medical Center, Boston, Massachusetts, USA bDepartment of Structural and Functional Biology, Institute of Biology, University of Campinas, Campinas, Sao Paulo, Brazil.
Abstract
PURPOSE OF REVIEW: Endothelial dysfunction is an early feature of vascular disease induced by cardiovascular risk factors (CRFs). In growing populations with obesity, diabetes, hypertension, and heart failure, mineralocorticoid receptor antagonism improves endothelial function. This review summarizes recent advances in our understanding of the specific role of endothelial cell mineralocorticoid receptor in vascular function in health and disease. RECENT FINDINGS: Using transgenic mice with mineralocorticoid receptor expression specifically modulated in endothelial cells, recent studies support the emerging concept that while endothelial cell mineralocorticoid receptor may be protective in health, in the presence of CRFs, endothelial cell mineralocorticoid receptor activity contributes to endothelial dysfunction and progression of vascular disease. Proposed mechanisms include a role for endothelial cell mineralocorticoid receptor in decreased nitric oxide production and bioavailability, increased vascular oxidative stress, regulation of epithelial sodium channels that enhance vascular stiffness, and increased endothelial cell adhesion molecules promoting inflammation. The role of endothelial cell mineralocorticoid receptor may also depend on the sex, race, or vascular bed involved. SUMMARY: Recent advances support the idea that endothelial cell mineralocorticoid receptor is a mediator of the switch from vascular health to disease in response to CRFs. Further investigation of the molecular mechanism is underway to identify therapeutic interventions that will limit the detrimental effects of endothelial cell mineralocorticoid receptor in patients at cardiovascular risk.
PURPOSE OF REVIEW: Endothelial dysfunction is an early feature of vascular disease induced by cardiovascular risk factors (CRFs). In growing populations with obesity, diabetes, hypertension, and heart failure, mineralocorticoid receptor antagonism improves endothelial function. This review summarizes recent advances in our understanding of the specific role of endothelial cell mineralocorticoid receptor in vascular function in health and disease. RECENT FINDINGS: Using transgenic mice with mineralocorticoid receptor expression specifically modulated in endothelial cells, recent studies support the emerging concept that while endothelial cell mineralocorticoid receptor may be protective in health, in the presence of CRFs, endothelial cell mineralocorticoid receptor activity contributes to endothelial dysfunction and progression of vascular disease. Proposed mechanisms include a role for endothelial cell mineralocorticoid receptor in decreased nitric oxide production and bioavailability, increased vascular oxidative stress, regulation of epithelial sodium channels that enhance vascular stiffness, and increased endothelial cell adhesion molecules promoting inflammation. The role of endothelial cell mineralocorticoid receptor may also depend on the sex, race, or vascular bed involved. SUMMARY: Recent advances support the idea that endothelial cell mineralocorticoid receptor is a mediator of the switch from vascular health to disease in response to CRFs. Further investigation of the molecular mechanism is underway to identify therapeutic interventions that will limit the detrimental effects of endothelial cell mineralocorticoid receptor in patients at cardiovascular risk.
Authors: P F Bodary; C Sambaziotis; K J Wickenheiser; S Rajagopalan; B Pitt; D T Eitzman Journal: Arterioscler Thromb Vasc Biol Date: 2006-01 Impact factor: 8.311
Authors: Ole Skøtt; Torben R Uhrenholt; Jeppe Schjerning; Pernille B L Hansen; Lasse E Rasmussen; Boye L Jensen Journal: Pharmacol Ther Date: 2006-01-18 Impact factor: 12.310
Authors: Vincent G DeMarco; Javad Habibi; Guanghong Jia; Annayya R Aroor; Francisco I Ramirez-Perez; Luis A Martinez-Lemus; Shawn B Bender; Mona Garro; Melvin R Hayden; Zhe Sun; Gerald A Meininger; Camila Manrique; Adam Whaley-Connell; James R Sowers Journal: Hypertension Date: 2015-05-26 Impact factor: 10.190
Authors: Fabian Nietlispach; Barbara Julius; Ruth Schindler; Alain Bernheim; Christoph Binkert; Wolfgang Kiowski; Hans Peter Brunner-La Rocca Journal: Hypertension Date: 2007-05-14 Impact factor: 10.190
Authors: Ane M Salvador; Tania Nevers; Francisco Velázquez; Mark Aronovitz; Bonnie Wang; Ana Abadía Molina; Iris Z Jaffe; Richard H Karas; Robert M Blanton; Pilar Alcaide Journal: J Am Heart Assoc Date: 2016-03-15 Impact factor: 5.501
Authors: Ana Paula Davel; Iris Z Jaffe; Rita C Tostes; Frederic Jaisser; Eric J Belin de Chantemèle Journal: Am J Physiol Heart Circ Physiol Date: 2018-06-29 Impact factor: 4.733
Authors: Texali C Garcia-Garduño; Jorge R Padilla-Gutierrez; Diego Cambrón-Mora; Yeminia Valle Journal: Int J Mol Sci Date: 2021-07-01 Impact factor: 5.923
Authors: Divya P Menon; Guanming Qi; Seung K Kim; M Elizabeth Moss; Krishna C Penumatsa; Rod R Warburton; Deniz Toksoz; Jamie Wilson; Nicholas S Hill; Iris Z Jaffe; Ioana R Preston Journal: Pulm Circ Date: 2021-06-18 Impact factor: 3.017